This stock has over 30 million shares outstanding and plenty of shares available to short. It's not one of those low floaters you're used to. The matket cap of this company isn't justified at those levels with only phase 2 trials completed.
I'd watch out for an announcement of a share offering to raise funds for the extra trials to come.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.